Latest News & Updates

Breaking News

9 hours ago
Vaibhavi M.

Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results For Camzyos In Adolescents

Roche Launches Cobas MPX-E Assay For Multi-Virus Blood Screening In CE-Mark Markets, Expands Diagnostic Portfolio

Vaibhavi M.

Novartis Reports Major Kidney Breakthrough As Fabhalta Shows Strong 2-Year Benefits In IgAN Trial

Simantini Singh Deo

Tonix Initiates Phase 1 Study Of TNX-1900 Targeting Trigeminal Neurovascular Activity

Vaibhavi M.

ImmunityBio’s QUILT-2.005 Trial Meets Power Goals, No Additional Enrollment Needed, IDMC Confirms Adequate Power In Bladder Cancer Study

Vaibhavi M.

Other trending news you may like to read

Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results For Camzyos In Adolescents

Bristol Myers Squibb reports Camzyos (mavacamten) met Phase 3 endpoints in adolescents with obstructive hypertrophic cardiomyopathy, improving LVOT gradient and cardiac function

Vaibhavi M.

Roche Launches Cobas MPX-E Assay For Multi-Virus Blood Screening In CE-Mark Markets, Expands Diagnostic Portfolio

Roche launches cobas MPX-E assay for blood screening, detecting HIV-1, HIV-2 and hepatitis B, C, E with high sensitivity to improve donor safety and lab efficiency in CE-mark markets

Vaibhavi M.

Novartis Reports Major Kidney Breakthrough As Fabhalta Shows Strong 2-Year Benefits In IgAN Trial

Novartis reports Fabhalta (iptacopan) shows sustained Phase III efficacy in IgA nephropathy, slowing eGFR decline, reducing kidney failure risk, and improving proteinuria over two years

Simantini Singh Deo

Tonix Initiates Phase 1 Study Of TNX-1900 Targeting Trigeminal Neurovascular Activity

Tonix Pharmaceuticals initiates Phase 1 study of TNX-1900 intranasal oxytocin therapy to evaluate trigeminal neurovascular activity linked to migraine and craniofacial pain.

Vaibhavi M.